Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandro Nuciforo

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Communications Medicine|July 5, 2022
Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case reportMarie-Anne Meier, Sandro Nuciforo, Mairene Coto-Llerena, et al.
NPJ Precision Oncology|November 3, 2023
Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancerMichele Garioni, Viviane J Tschan, Lauriane Blukacz, et al.
Hepatology Communications|July 24, 2019
Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating TumorsTanja Blumer, Isabel Fofana, Matthias S Matter, et al.
Ebiomedicine|October 5, 2024
Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparibXiaonan Zhang, Natallia Rameika, Lei Zhong, et al.
Cell|October 7, 2023
Arginine reprograms metabolism in liver cancer via RBM39Dirk Mossmann, Christoph Müller, Sujin Park, et al.
Nature Communications|May 4, 2022
Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stagesCharlotte K Y Ng, Eva Dazert, Tuyana Boldanova, et al.
Gastro Hep Advances|February 6, 2025
Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor EffectsLouise Kaldjob-Heinrich, Sandro Nuciforo, Steffen Lemke, et al.
Molecular Oncology|December 4, 2021
Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinomaJohn Gallon, Mairene Coto-Llerena, Caner Ercan, et al.
Nature Communications|December 19, 2019
LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold functionFengyuan Tang, Ruize Gao, Beena Jeevan-Raj, et al.
Nature Communications|August 25, 2025
The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically activeCelia Sequera, Margherita Grattarola, Floriane Cannet, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Communications Medicine|July 5, 2022
Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case reportMarie-Anne Meier, Sandro Nuciforo, Mairene Coto-Llerena, et al.
NPJ Precision Oncology|November 3, 2023
Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancerMichele Garioni, Viviane J Tschan, Lauriane Blukacz, et al.
Hepatology Communications|July 24, 2019
Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating TumorsTanja Blumer, Isabel Fofana, Matthias S Matter, et al.
Ebiomedicine|October 5, 2024
Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparibXiaonan Zhang, Natallia Rameika, Lei Zhong, et al.
Cell|October 7, 2023
Arginine reprograms metabolism in liver cancer via RBM39Dirk Mossmann, Christoph Müller, Sujin Park, et al.
Nature Communications|May 4, 2022
Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stagesCharlotte K Y Ng, Eva Dazert, Tuyana Boldanova, et al.
Gastro Hep Advances|February 6, 2025
Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor EffectsLouise Kaldjob-Heinrich, Sandro Nuciforo, Steffen Lemke, et al.
Molecular Oncology|December 4, 2021
Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinomaJohn Gallon, Mairene Coto-Llerena, Caner Ercan, et al.
Nature Communications|December 19, 2019
LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold functionFengyuan Tang, Ruize Gao, Beena Jeevan-Raj, et al.
Nature Communications|August 25, 2025
The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically activeCelia Sequera, Margherita Grattarola, Floriane Cannet, et al.
Pageof 3